In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis

Clinical Chemistry

Volumn 59, Issue 7, 2013, Pages 1108-1117

  Scheidweiler, Karl B ^a   Schwope, David M ^a,b   Karschner, Erin L ^a,b   Desrosiers, Nathalie A ^a   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b Aegis Sciences Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; 11 NOR 9 CARBOXY TETRAHYDROCANNABINOL GLUCURONIDE; CANNABIDIOL; CANNABINOL; CANNABIS; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL DERIVATIVE; TETRAHYDROCANNABINOL GLUCURONIDE; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANNABIS SMOKING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG STABILITY; FEMALE; FRIEDMAN TEST; HUMAN; IN VITRO STUDY; MALE; OUTCOME ASSESSMENT; ROOM TEMPERATURE;

BLOOD SPECIMEN COLLECTION; CANNABIDIOL; CANNABINOIDS; CANNABINOL; DRUG STABILITY; FEMALE; GLUCURONIDES; HUMANS; MALE; MARIJUANA SMOKING; PLASMA; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL;

CANNABIS;

EID: 84879723390     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.201467     Document Type: Article

References (27)

1. Skopp G, Potsch L. Stability of 11-nor-delta(9)-carboxy- tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem 2002;48:301-6. (Pubitemid 34107267)
2. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-35.
3. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9- tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992;16:283-90.
4. Huestis MA, Barnes A, Smith ML. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9- tetrahydrocannabinol concentrations. Clin Chem 2005;51:2289-95. (Pubitemid 41692572)
5. Huestis MA, Elsohly M, Nebro W, Barnes A, Gustafson RA, Smith ML. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit 2006;28:540-4. (Pubitemid 44181488)
6. Schwilke EW, Karschner EL, Lowe RH, Gordon AM, Cadet JL, Herning R, Huestis MA. Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem 2009;55:1188-95.
7. Johnson JR, Jennison TA, Peat MA, Foltz RL. Stability of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 1984;8:202-4. (Pubitemid 14035342)
8. Christophersen AS. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 1986;10:129-31. (Pubitemid 17100544)
9. Grauwiler SB, Scholer A, Drewe J. Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B 2007;850:515-22. (Pubitemid 46618202)
10. Wong AS, Orbanosky MW, Reeve VC, Beede JD. Stability of delta-9-tetrahydrocannabinol in stored blood and serum: analysis of cannabinoids. Research Monograph. Rockville: National Institute on Drug Abuse 1982:119-24.
11. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011;57:1406-14.
12. Schwope DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401:1273-83.
13. Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwarter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 2011;46:163-71.
14. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003;25:1-16. (Pubitemid 36139819)
15. Andrews R, Paterson S. Production of identical retention times and mass spectra for delta-9-tetrahydrocannabinol and cannabidiol following derivatization with trifluoracetic anhydride with 1,1,1,3,3,3- hexafluoroisopropanol. J Anal Toxicol 2012;36:61-5.
16. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9- tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007;31:477-85. (Pubitemid 350164290)
17. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 1995;19:292-8.
18. Mareck U, Haenelt N, Geyer H, Guddat S, Kamber M, Brenneisen R, et al. Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal 2009;1:505-10.
19. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16:276-82.
20. Cocchetto DM, Owens SM, Perez-Reyes M, Di Guiseppi S, Miller LL. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 1981;75:158-64. (Pubitemid 12228823)
21. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology 1981;74:208-12. (Pubitemid 11034573)
22. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma levels of delta-9-tetrahydrocannabinol after intravenous, oral and smoke administration. Clin Pharmacol Ther 1980;28:409-16. (Pubitemid 10007024)
23. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Terminal elimination plasma half-life of delta-1-tetrahydrocannabinol (delta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989;37:273-7. (Pubitemid 19242734)
24. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav 1990;37:561-5.
25. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006;28:545-51. (Pubitemid 44181489)
26. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, et al. Delta9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55:2180-9.
27. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta-9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57:66-75. Health